Pharmaceutics 2010, 2(4), 364-388; doi:10.3390/pharmaceutics2040364

Drug Development for Pediatric Populations: Regulatory Aspects

* email,  and
Received: 15 October 2010; in revised form: 18 November 2010 / Accepted: 24 November 2010 / Published: 29 November 2010
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Abstract: Pediatric aspects are nowadays integrated early in the development process of a new drug. The stronger enforcement to obtain pediatric information by the regulatory agencies in recent years resulted in an increased number of trials in children. Specific guidelines and requirements from, in particular, the European Medicines Agency (EMA) and the Food and Drug Administration (FDA) form the regulatory framework. This review summarizes the regulatory requirements and strategies for pediatric drug development from an industry perspective. It covers pediatric study planning and conduct, considerations for first dose in children, appropriate sampling strategies, and different methods for data generation and analysis to generate knowledge about the pharmacokinetics (PK) and pharmacodynamics (PD) of a drug in children. The role of Modeling and Simulation (M&S) in pediatrics is highlighted—including the regulatory basis—and examples of the use of M&S are illustrated to support pediatric drug development.
Keywords: pediatrics; children; pediatric drug development; pediatric legislation; health authorities; regulatory guidelines; PIP; clinical studies; Modeling and Simulation; PK/PD  modeling
PDF Full-text Download PDF Full-Text [160 KB, Updated Version, uploaded 30 November 2010 11:07 CET]
The original version is still available [164 KB, uploaded 29 November 2010 17:24 CET]

Export to BibTeX |

MDPI and ACS Style

Zisowsky, J.; Krause, A.; Dingemanse, J. Drug Development for Pediatric Populations: Regulatory Aspects. Pharmaceutics 2010, 2, 364-388.

AMA Style

Zisowsky J, Krause A, Dingemanse J. Drug Development for Pediatric Populations: Regulatory Aspects. Pharmaceutics. 2010; 2(4):364-388.

Chicago/Turabian Style

Zisowsky, Jochen; Krause, Andreas; Dingemanse, Jasper. 2010. "Drug Development for Pediatric Populations: Regulatory Aspects." Pharmaceutics 2, no. 4: 364-388.

Pharmaceutics EISSN 1999-4923 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert